Sequenom Discloses Mishandling of Test Data; Shares Plummet

Sequenom's shares took a beating on Thursday after the firm disclosed that four employees are suspected of mishandling R&D data on its Down syndrome test. The firm said that it would delay the launch of the test until later in the year.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories